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OBJECTIVE—Overactivity of the Forkhead transcription factor
FoxO1 promotes diabetic hyperglycemia, dyslipidemia, and acute-
phase response, whereas suppression of FoxO1 activity by insulin
may alleviate diabetes. The reported efﬁcacy of long-chain fatty
acyl (LCFA) analogs of the MEDICA series in activating AMP-
activated protein kinase (AMPK) and in treating animal models of
diabesity may indicate suppression of FoxO1 activity.
RESEARCH DESIGN AND METHODS—The insulin-sensitizing
and anti-inﬂammatory efﬁcacy of a MEDICA analog has been
veriﬁed in guinea pig and in human C-reactive protein (hCRP)
transgenic mice, respectively. Suppression of FoxO1 transcrip-
tional activity has been veriﬁed in the context of FoxO1- and
STAT3-responsive genes and compared with suppression of FoxO1
activity by insulin and metformin.
RESULTS—Treatment with MEDICA analog resulted in total
body sensitization to insulin, suppression of lipopolysaccharide-
induced hCRP and interleukin-6–induced acute phase reactants
and robust decrease in FoxO1 transcriptional activity and in
coactivation of STAT3. Suppression of FoxO1 activity was
accounted for by its nuclear export by MEDICA-activated AMPK,
complemented by inhibition of nuclear FoxO1 transcriptional ac-
tivity by MEDICA-induced C/EBPb isoforms. Similarly, insulin
treatment resulted in nuclear exclusion of FoxO1 and further
suppression of its nuclear activity by insulin-induced C/EBPb iso-
forms. In contrast, FoxO1 suppression by metformin was essen-
tially accounted for by its nuclear export by metformin-activated
AMPK.
CONCLUSIONS—Suppression of FoxO1 activity by MEDICA
analogs may partly account for their antidiabetic anti-inﬂammatory
efﬁcacy. FoxO1 suppression by LCFA analogs may provide a mo-
lecular rational for the beneﬁcial efﬁcacy of carbohydrate-restricted
ketogenic diets in treating diabetes. Diabetes 60:1872–1881, 2011
O
veractivity of the Forkhead transcription factor
FoxO1 promotes diabetic hyperglycemia and
dyslipidemia, combined with pancreatic insufﬁ-
ciency (recently reviewed in [1]). Speciﬁcally,
FoxO proteins promote hepatic glucose production be-
cause of transcriptional transactivation of genes coding
for rate-limiting gluconeogenic enzymes (2,3), accompa-
nied by FoxO1-induced switch from muscle carbohydrate
to fatty acid metabolism with concomitant decrease in
glucose utilization (4). Further to diabetic hyperglycemia,
FoxO1 may promote diabetic dyslipidemia as a result of
increased lipoprotein production complemented by inhibi-
tion of plasma lipoprotein clearance, as a result of tran-
scriptional activation of the microsomal triglyceride transfer
protein (5) and of apolipoprotein CIII (6), respectively.
Suppression of pancreatic duodenal homeobox-1 expres-
sion by FoxO1 (7) may further limit the expansion of b-cell
mass in response to peripheral insulin resistance. More-
over, FoxO1 may enhance the acute phase/inﬂammatory
response to cytokines (e.g., interleukin [IL]-6, tumor ne-
crosis factor [TNF]-a) and growth factors (e.g., epidermal
growth factor [EGF], IGF) as a result of coactivation of
STAT3 (8,9), thus promoting the macrovascular disease of
diabetes (10). STAT3-induced SOCS3 also may result in its
binding and inhibition of insulin receptor signaling, com-
plemented by proteasomal degradation of insulin receptor
substrate [IRS]1/2 (11,12). Insulin activity in maintaining
balanced carbolipid metabolism and in restraining cytokine-
induced inﬂammation is partly accounted for by phos-
phorylation of FoxO1 (T24, S256, S319) by activated protein
kinase B (PKB)/Akt, resulting in its nuclear exclusion, poly-
ubiquitination, and proteasomal degradation (reviewed
in [1]).
Carbohydrate-restricted ketogenic diets were used as
sole treatment for diabetes before the insulin era begin-
ning in 1922 and are reported to outweigh the performance
of isocaloric high-carbohydrate fat-restricting diets in al-
leviating glycemic control, dyslipidemia, and insulin re-
sistance in type 2 diabetes (13–15). The efﬁcacy of ketogenic
diets is surprising in view of their inherent lipotoxic poten-
tial (16). This apparent paradox may be resolved by pro-
posing that the lipotoxicity of high-fat diets may be because
of downstream fatty acyl metabolites (e.g., diglycerides,
triglycerides, ceramide) derived under conditions of car-
bohydrate and insulin excess, whereas the free long-chain
fatty acid (LCFA) precursors (or their respective LCFA-
CoA thioesters) may account for the surprising efﬁcacy of
carbohydrate-restricted ketogenic diets, if not allowed to
be further metabolized into downstream lipotoxic products.
Alternatively, synthetic LCFA that are neither esteriﬁed into
lipids nor b-oxidized may mimic the proposed intrinsic efﬁ-
cacy of free LCFA/LCFA-CoA in the diabetes context.
MEDICA analogs (17–22) consist of long-chain, a,v-
dicarboxylic acids, tetramethyl-substituted in the aa9 (Maa)
or bb9 carbons [HOOC-C(a9)-C(b9)-(CH2)n-C(b)-C(a)-COOH].
MEDICA analogs may be thioesteriﬁed to their respective
CoA-thioesters, but these are not esteriﬁed into lipids, nor
converted into ceramides, whereas the methyl-substitutions
at the aa9 or bb9 positions block their b-oxidation. Treat-
ment with MEDICA analogs results in the formation of
endogenous MEDICA-CoA thioesters, but not in depletion
of intracellular CoA (23). MEDICA analogs are mostly
excreted in bile as respective glucuronides (J.B.-T.,
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ORIGINAL ARTICLEunpublished data). MEDICA analogs have been pre-
viously reported to suppress hepatic glucose and lipopro-
tein production, with a concomitant increase in total body
glucose uptake and plasma lipoprotein clearance in several
animal models of diabesity (e.g., Zucker, cp/cp, db/db, ob/ob)
(17–22). The insulin-mimetic activity of MEDICA analogs
and of ketogenic diets in the diabesity context prompted
our interest in FoxO1 as putative target of LCFA/MEDICA.
RESEARCH DESIGN AND METHODS
Animals. Male guinea pigs (GP) (HsdPoc:DH) weighing 500 g were individually
housed with free access to water and standard GP diet (Teklad 2040S). GP were
cannulatedthrough the carotidarteryandjugularveinunderketamine(75 mg/kg
body wt [BW]), xylazine (6 mg/kg BW), and rimadyl (1.5 mg/kg BW) anesthesia.
After catheter placement animals were allowed to recover for 7–14 days until
exceeding their initial body weight by 80 g. Cannule patency was maintained
every 10–14 days by washing with heparinized saline (25 units/mL), followed by
clamping the cannules with heparinized glycerol (75% glycerol, 20% saline, and
5% heparin; 5,000 units/mL). Maa was dosed daily by gavage by stepwise
addition of the drug during a period of 2 weeks, reaching a ﬁnal daily dose of
10 mg/kg BW in 1% carboxymethylcellulose (CMC). The ﬁnal dose was main-
tained for a period of 4–8 weeks. Age-matched nontreated animals were dosed
by 1% CMC.
Human C-reactive protein (CRP) transgenic mice (hCRPtg) (24) aged 10–12
weeks were fed standard rodent diet (Teklad 2018) with/without 0.06% (w/w)
Maa mixed in the diet or were dosed daily by gavage with 60 mg/kg BW Maa
in 1% CMC or with vehicle. Age-matched SD rats weighing 170–250 g were
dosed daily by gavage with 80 mg/kg BW of Maa in 1% CMC or with vehicle.
Upon death, livers were frozen immediately in liquid nitrogen and kept at
270°C.
Animal care and experimental procedures were in accordance with the
accredited animal ethics committee of the Hebrew University.
Cultured cells and transfection assays. HepG2, Hep3B, COS7 cells, and
mouse embryo ﬁbroblasts (MEF) were cultured in Dulbecco’s modiﬁed Eagle’s
medium (DMEM) supplemented with 10% FCS, 2 mM glutamine, 100 units/mL
penicillin, and 0.1 mg/mL streptomycin. H4IIE cells were grown in 1:1 mixture
of DMEM and F-12 medium, supplemented with 10% FCS.
COS7cells culturedina24-well plateweretransfectedwithreporterplasmids
for FoxO1 [FRE3-TK-LUC], consisting of three copies of the FoxO1 response
element (FRE) of the IGFBP1 promoter (0.3 mg) (25), STAT3 [M67-TATA-TK-
LUC] (0.3 mg) (26), or GAL4 [GAL4(UAS)5 -LUC] (0.6 mg) as indicated, together
with expression plasmids for constitutive STAT3 [FLAG-STAT3-C] (0.05 mg)
(26), wild-type GFP-FoxO1(T24, S256, S319) [FoxO1(TSS)] (0.05 mg) (27), GFP-
FoxO1(T24A, S256A, S319A) [FoxO1(AAA)] (0.05 mg) (27), GAL4-FoxO1
(Daa211–655, S256, S319) [GAL4-FoxO1(SS)] (0.05 mg), or GAL4-FoxO1
(Daa211–655, S256A, S319A) [GAL4-FoxO1(AA)] (0.05 mg) as indicated, using
Mirus reagent (Mirus Corporation). The total amount of DNA was kept constant
by supplementing with empty plasmid. Six h after transfection, culture medium
was replaced with serum-free DMEM containing 0.2% fatty acid-free albumin,
supplemented with vehicle, Maa, or metformin as indicated, and further in-
cubated for 16 h. For insulin treatment, transfected cells were cultured for 24 h
in serum-free DMEM with insulin as indicated, being replenished every 12 h.
Luciferase values were normalized to b-galactosidase activity.
CHOP
+/+ and CHOP
2/2 MEF (28) cultured in a 24-well plate were transfected
with FoxO1 reporter plasmid [FRE3-TK-LUC] (1.65 mg) and FLAG-FoxO1 (AAA)
(0.05 mg) expression plasmid using jetPEI (Polyplus Transfection). Six h after
transfection the culture medium was supplemented with vehicle or Maa as
indicated, and the cells were further incubated for 40 h before analysis.
Cell lysis, SDS-PAGE, and Western blotting. Liver and cell lysates were
prepared and analyzed by SDS-PAGE/Western blotting (22,29). Presented lanes
of the same blot were rearranged in some ﬁgures to condense the pre-
sentation.
Nuclear extracts and immunoprecipitation. Sixteenhaftertransfectionwith
theindicatedreporter/expressionplasmidscellswerewashedtwicewithcoldPBS
andlysedinlysisbufferA(Hepes[10mM,pH8],KCl[10mM],dithiothreitol[1mM],
EDTA [0.1 mM], EGTA [0.1 mM], NaF [50 mM], NaPPi [5 mM], sodium vanadate
[1 mM], bpVphen [40 nM], phenylmethylsulfonylﬂuoride [1 mM], and protease
inhibitor mix [Sigma]), followed by incubation for 15 min on ice. After the
additionof1%NP40,thecellswerevortexedfor10sandcentrifugedfor3minat
3,000g,4°C.ThepelletwasresuspendedinlysisbufferB(Hepes[20mM,pH8],
NaCl [400 mM], dithiothreitol [1 mM], EDTA [1 mM], EGTA [1 mM], NaF
[50 mM], NaPPi [5 mM], sodium vanadate [1 mM], bpVphen [40 nM], phenyl-
methylsulfonylﬂuoride [1 mM], and protease inhibitor mix) and kept on ice
for 15 min with continuous shaking. Insoluble material was removed by
centrifugation at 13,400g for 5 min. Respective transcription factors were
immunoprecipitated by incubating 200 mg nuclear extract with Sepharose A/G
beads (Pierce Biotechnology) for 30 min at 4°C (preclearing), followed by
incubating the extract overnight at 4°C with Sepharose A/G preloaded with
respective antibody. The beads were then washed three times with lysis buffer
B and two times with TBS (25 mM Tris, pH 7.2; 150 mM NaCl), and were boiled
in SDS sample buffer for 5 min. Immunoprecipitated proteins were analyzed
by SDS-PAGE/Western blotting.
Plasmids. rAMPKa1(D157A) mutant [DN-AMPK] was prepared by mutating
rAMPKa1 using the QuikChange Site-Directed Mutagenesis kit (Stratagene,
CA) (30). STAT3 [M67-TATA-TK-LUC] reporter plasmid, consisting of four
copies of the sequence (GGTTCCCGTAAATGCATCA) and a minimal thymi-
dine kinase promoter (26), and FLAG-STAT3-C expression plasmid were from
J.E. Darnell Jr. (Rockefeller University, NY). CHOP expression plasmids (31)
were from A. Aronheim (Technion, Israel). pSCT-LAP and pSCT-LIP expres-
sion plasmids (32) were from J. Orly (Hebrew University, Israel). GAL4
[(UAS)5-LUC] construct consisted of ﬁve Gal4 Upstream Activator Sequences
(UAS) upstream of Luciferase reporter.
Real-time PCR. Total RNA from liver and cultured cells was prepared
and analyzed by RT-PCR as previously described (22). The following primers
were used: hCRP sense 59-TCATGCTTTTGGCCAGACAG-39 and antisense
59-GGTCGAGGACAGTTCCGTGT-39; b-actin sense 59-ATAGCACAGCCTGGA-
TAGCAACGTAC-39 and antisense 59-CACCTTCTACAATGAGCTGCGTGTG-39;
mouse b-actin sense 59-GGCTGTATTCCCCTCCATCG-39 and antisense
59-CCAGTTGGTAACAATGCCATGT-39; mouse serum amyloid P (SAP) sense
59-AGACAGACCTCAAGAGGAAAGT-39 and antisense 59-AGGTTCGGAAACAC-
AGTGTAAAA-39; mouse serum amyloid A (SAA)2 sense 59-TGGCTGGAAA-
GATGGAGACAA-39 and antisense 59-AAAGCTCTCTCTTGCATCACTG-39;
mouse ﬁbrinogen sense 59-AGTGTTGTGTCCTACGGGATG-39 and antisense
59-CTGAGGAGGTATCGGAAACAGA-39.
Materials. Anti- STAT3, FoxO1, P-FoxO1(T24)/P-FoxO3a(T32), rabbit C/EBPb/
LAP, and CHOP antibodies were from Cell Signaling Technology. Anti-tubulin
antibody was from Sigma. Anti-mouse C/EBPb antibody was from Santa Cruz.
b-Galactosidase determination kit was from Bio-Rad. Luciferase determination
kit was from Biological Industries. hCRP(hs) ELISA kit was from DRG
Instruments. Insulin RIA kit was from MD-Biomedicals.
Data analysis. Signiﬁcance was analyzed by paired t test or by Mann-Whitney
U test.
RESULTS
MEDICA analogs have previously been reported to in-
crease total body glucose uptake in several animal models
of leptin or leptin receptor defects (17–22). However, be-
cause leptin or leptin receptor defects do not account for
human diabesity, we were looking for an alternative ani-
mal model for studying sensitization to insulin by MEDICA
analogs. GP provide a rodent model that is relevant to
humans in light of their human-like proﬁle of plasma lip-
oproteins and lack of liver peroxisomal proliferation in re-
sponse to peroxisome proliferator–activating receptor-a
ligands (33,34). Carbohydrate-restricted high-fat diet also
has recently been reported to increase the Quantitative
Insulin Sensitivity Check Index (Quicki) (35) of normo-
glycemic GP (36). Indeed, treatment of GP with the
MEDICA analog Maa [a,a9-tetramethyl hexadecanedioic
acid, HOOC-C(CH3)2-(CH2)12-C(CH3)2-COOH] resulted
in twofold increase in the rate of infused glucose (M [in
mg/min/kg BW]) required to maintain euglycemia under
conditions of clamped hyperinsulinemia (Fig. 1A). More-
over, average plasma insulin under hyperinsulinemic
clamp conditions (I [ng/mL]) were 14 6 3a n d2 06 3f o r
Maa-treated and nontreated GP, respectively, implying
M-to-I ratio of 2.8 6 0.7 and 0.8 6 0.1, respectively (P =
0.011). Furthermore, the insulin-sensitizing efﬁcacy of Maa
actually exceeds the 3.5-fold increase in M/I, since M values
for nontreated animals were derived under hyperinsulinemic-
euglycemic clamp conditions (plasma glucose 90–106 mg/dL),
whereas M values for Maa-treated animals were derived
while maintaining plasma glucose at 67–87 mg/dL, as a re-
sult of robust increase in glucose uptake that could not be
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tion to insulin was further demonstrated by dose-dependent
insulin-like suppression of dexamethasone/cAMP-induced
glucose production in H4IIE hepatocytes by Maa (Fig. 1B),
in line with suppression of glucose-6-phosphatase expres-
sion by Maa (22). These results complement our pre-
vious ﬁndings indicating sensitization to insulin by Mbb
[b,b9-tetramethyl hexadecanedioic acid] in animal models
of diabesity (19,20).
Maa suppression of the acute phase response induced
by LPS/NF-kB/IL-6/STAT3 transduction pathway (reviewed
in [37]) has been veriﬁed here in vivo in hCRP transgenic
mice, which carry a 31-kb ClaI fragment of human genomic
DNA consisting of the CRP gene, 17 kb of 59-ﬂanking
sequence, and 11.3 kb of 39-ﬂanking sequence (24). LPS-
induced plasma hCRP was signiﬁcantly suppressed by
in vivo treatment with Maa (Fig. 2A). Similarly, IL-6/IL-1-
induced expression of hCRP (Fig. 2B)o rS O C S 3( n o t
shown) was robustly suppressed by Maa in Hep3B cells,
where in contrast with HepG2, hCRP is increased in re-
sponse to IL-6. Furthermore, IL-6–induced expression of
the acute-phase reactants mSAA2 and mSAP was signiﬁ-
cantly suppressed by in vivo treatment of hCRPtg with
Maa (Fig. 2C), implying Maa suppression of the acute
phase response induced by STAT3.
To test whether suppression of FoxO1 function may
mediate effects of MEDICA compounds, we used reporter
plasmids driven by the FRE of the IGFBP1 gene promoter
(25) to probe transcriptional transactivation by FoxO1, or
the STAT3-responsive M67 sequence (26) to probe co-
activation of STAT3 (Fig. 3). Because FoxO1 transcriptional
activity may be affected by its nuclear exclusion as well
as by its nuclear transcriptional activity, COS7 cells that
lack endogenous FoxO1 were transfected with either an
expression plasmid for wild-type foxO1(T24, S256, S319)
[FoxO1(TSS)] or with FoxO1(T24, S256A, S319A) mutant
[FoxO1(AAA)] that preferentially translocates to the nu-
cleus as a result of loss of the three Akt phosphorylaton
sites (T24, S256, S319) (1). Because Maa transduces
sensitization to insulin by activating AMPK, its effect
was compared with that of metformin (22). As shown in
Fig. 3A, while being similarly overexpressed (not shown),
transcriptional transactivation of the FRE reporter in-
creased 600-fold by FoxO1(AAA) as compared with 40-
fold increase by wild-type FoxO1(TSS), indicating that
transactivation by FoxO1 is indeed strongly affected by
its phosphorylation at Akt sites. Transactivation of the
FRE reporter by wild-type FoxO1(TSS) was 50% inhibited
by metformin, whereas transactivation by the FoxO1(AAA)
mutant was only slightly inhibited, albeit signiﬁcantly
(Fig. 3A), implying that suppression of FoxO1 transcrip-
tional activity by metformin may essentially be ascribed
to its nuclear exclusion. In contrast with metformin, ex-
pression of the FRE reporter, driven by either the wild-type
FoxO1(TSS) or the FoxO1(AAA) mutant, was 90% inhibited
by Maa (Fig. 3A), implying inhibition of nuclear FoxO1
transcriptional activity independently of its nuclear export.
The robust efﬁcacy of Maa in suppressing FoxO1 tran-
scriptional activity is further underscored by realizing its
high binding afﬁnity to medium albumin (estimated to be
.99%, independently of Maa concentrations in the range of
0 to 0.9 mmol/L [J.B.-T., unpublished results]), resulting in
FIG. 1. Insulin-sensitizing activity of Maa. A: GP were treated with Maa as described in RESEARCH DESIGN AND METHODS. Fasting plasma glucose
amounted to 112 6 7 mg% and 108 6 8 mg% in nontreated and Maa-treated GP, respectively. Fasted GP were primed through the jugular vein
cannula with Humulin R insulin in saline/0.2% BSA (fatty acid free), followed by constant infusion of 10–80 mU/kg BW/min for 180 min. Plasma
glucose was monitored by Elite glucometer every 10 min and maintained by infusing a solution of 50% glucose in saline at a variable rate, up to
50 mL/min. M, the rate of infused glucose (mg/kg BW/min) required to maintain blood glucose under conditions of clamped hyperinsulinemia.
M values for all nontreated animals (n = 7) were derived under hyperinsulinemic-euglycemic clamp conditions (plasma glucose 90–106 mg/dL,
plasma insulin 20 6 3 ng/mL). M values for Maa-treated animals (n = 6) were derived under hyperinsulinemic-hypoglycemic clamp conditions
(plasma glucose 67–87 mg/dL, plasma insulin 14 6 3 ng/mL), as a result of robust increase in glucose uptake that could not be satisﬁed by maximal
rates of glucose infusion (50 mL/min). Respective means are denoted by line (P < 0.05). B: Lactate/pyruvate-dependent glucose production (ar-
bitrary units) induced by dexamethasone/8-(4-chlorophenylthio)-cAMP was determined in H4IIE cells as previously described (22), in the pres-
ence and absence of Maa and insulin as indicated. Representative experiment in triplicates. Mean 6 SE. *Signiﬁcant as compared with nontreated
cells (P < 0.05).
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medium.
Suppression of FoxO1 coactivation of STAT3 by Maa or
metformin was veriﬁed in COS7 cells transfected with ex-
pression plasmids for wild-type FoxO1(TSS) or FoxO1
(AAA), together with a STAT3 reporter plasmid and an
expression plasmid for constitutively active STAT3 [STAT3-C],
which translocates to the nucleus independently of its
phosphorylation (26). In line with a previous report (9),
transactivation of the STAT3 reporter by STAT3-C was
robustly activated by added FoxO1(TSS), and even more
so by FoxO1(AAA) (Fig. 3B). Coactivation of STAT3-C by
wild-type FoxO1(TSS) was inhibited by Maa or metfor-
min, whereas coactivation of STAT3-C by FoxO1(AAA)
was suppressed by Maa, but not by metformin, conform-
ing to the proﬁle of the two effectors in the context of
the FRE reporter plasmid (Fig. 3A). Hence, although Maa
and metformin may share a similar mode of action in
exporting nuclear FoxO1, the transcriptional activity of
nuclear FoxO1 is speciﬁcally inhibited by Maa, but not by
metformin.
Export of nuclear FoxO1 by Maa or metformin, as
compared with insulin (1), was further pursued in GFP-
FoxO1-transfected HepG2 cells by evaluating the nuclear-
to-cytosolic ratio of GFP-FoxO1, using ﬂuorescence
microscopy. The 1:1 nuclear-to-cytosolic ratio of FoxO1 in
HepG2 cells allowed for evaluating translocation in both
directions. All three effectors, namely, Maa, metformin, and
insulin, suppressed the nuclear/cytosolic ratio of FoxO1
(Fig. 4A and B), implying its nuclear exclusion. In contrast
with insulin, where export of nuclear FoxO1 remained
unaffected by coexpression of dominant-negative AMPK
(DN-AMPK), that of Maa or metformin was abrogated by
DN-AMPK(Fig.4AandB),indicatingthatnuclearexclusion
of FoxO1 was driven by Maa- or metformin-activated AMPK
(22). The mode of action of Maa- or metformin-activated
AMPK in exporting nuclear FoxO1 has been probed by the
phosphorylationoftheT24consensusAktsiteofendogenous
FoxO1 in HepG2 cells. Phosphorylation of FoxO1(T24) is re-
quiredforrecruitmentof14–3-3proteins,whichmasknuclear
localization signals and promote cytoplasmic localization of
FoxO1(38).IncontrastwithFoxO1(T24)phosphorylationby
insulin, FoxO1(T24) remained unphosphorylated by Maa or
metformin under conditions of activating AMPK (Fig. 4C),
implying that in contrast with insulin-, nuclear FoxO1 export
by AMPK was not transduced by Akt activation. In line with
the low stability of FoxO1 as a result of insulin-, shear
stress- or AICAR-activated AMPK (39,40), nuclear exclu-
sion of FoxO1 by Maa-activated AMPK was accompanied
by lower FoxO1 content in human umbilical vein epithelial
cells (HUVEC) (not shown), as well as in livers of Maa-
treated SD rats and hCRP transgenic mice (Fig. 4D). FoxO1
expression remained unaffected by Maa (not shown). Hence,
nuclear exclusion of wild-type FoxO1(TSS) by Maa-o r
metformin-activated AMPK may partly account for their
suppression of FoxO1 transcriptional activity.
FIG. 2. Inhibition of the acute phase response by Maa. A: Male hCRP transgenic mice were fed for 3 weeks with Maa (n = 7) mixed in the diet or
left untreated (n = 7) as described in RESEARCH DESIGN AND METHODS. LPS (25 mg) was injected intraperitoneally as indicated and the mice were killed
18 h later. LPS-induced plasma hCRP was determined as described in RESEARCH DESIGN AND METHODS. Respective means are denoted by lines (P <
0.05). B: Hep3B cells were used for evaluating Maa effects in suppressing IL6-induced CRP since HepG2 cells fail to respond to IL6. Hep3B cells
were incubated for 24 h in the absence (black bars) and presence (white bars) of 200 mmol/L Maa, 10 ng/mL IL-6, and 1 ng/mL IL-1 as indicated.
mRNA normalized to b-actin was quantiﬁed by real time PCR as described in RESEARCH DESIGN AND METHODS. mRNA content of nontreated cells is
deﬁned as 1.0. Representative experiment in triplicates. Mean 6 SE. *Signiﬁcant as compared with nontreated cells (P < 0.05). C: Male hCRP
transgenic mice were dosed daily by gavage for 2 weeks with vehicle (black bars) or 60 mg/kg BW of Maa (empty bars) as described in RESEARCH
DESIGN AND METHODS. IL-6 (500 ng) was injected intraperitoneally, and the mice were killed 18 h later. Mouse hepatic SAA2, SAP, and ﬁbrinogen
transcripts normalized to b-actin were determined by real time PCR as described in RESEARCH DESIGN AND METHODS. mRNA content of nontreated
animals is deﬁned as 1.0. Mean 6 SE (n = 8). *Signiﬁcant as compared with vehicle-treated mice (P < 0.05).
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FoxO1 by Maa was further pursued by deﬁning the FoxO1
domain(s) required for suppressing nuclear FoxO1 activ-
ity. Maa failed to suppress transactivation of a GAL4 re-
porter plasmid by GAL4-FoxO1(SS) (Daa211–655, S256,
S319) or GAL4-FoxO1(AA) (Daa211–655, S256A, S319A)
expression plasmid chimera, consisting of the GAL4 DNA
binding domain (DBD) and nuclear localization signal in-
frame with the COOH-terminal transactivation domains of
FoxO1 (Fig. 5A). This result indicates that Maa does not
disrupt the function of COOH-terminal transactivation
domains in FoxO1, and that NH2-terminal domains of
FoxO1 are required for Maa inhibitory activity in the
context of FRE promoters. Similarly, in contrast with
coactivation of STAT3 by FoxO1(AAA), the GAL4-FoxO1
(Daa211–655, S256A, S319A) expression plasmid chi-
mera failed to coactivate STAT3 (Fig. 5B). This result
indicates that, in addition to COOH-terminal domains of
FoxO1 previously reported to be required for STAT3 coac-
tivation by FoxO1 (9), NH2-terminal elements of FoxO1 are
also required for STAT3 coactivation by FoxO1, and hence
for STAT3 inhibition by Maa.
Because amino acids 1–211 of FoxO1 consist of part of
FoxO1 DBD (aa156–265), including helix3 that interacts
directly with FRE, as well as of domains required for intra-
and intermolecular protein-protein interactions (41), we
also examined whether Maa might suppress nuclear
FoxO1 activity by interfering with its binding to FRE
sites and/or its interaction with STAT3. FoxO1 binding to
FRE/IGFBP-1 remained unaffected by Maa as veriﬁed by
gel-shift analysis using nuclear extracts of Maa-treated
cells (Fig. 5C). Similarly, FoxO1 association with STAT3
analyzed by coimmunoprecipitation remained unaffected
by Maa treatment (Fig. 5D), indicating that Maa sup-
pression of nuclear FoxO1 activity was not accounted
for by abrogating FoxO1 binding to its FRE or to STAT3.
In view of these ﬁndings, the mode of suppression of
nuclear FoxO1 activity by Maa was further pursued by
searching for a third partner that could be recruited by
Maa to FoxO1 or to the FoxO1/STAT3 heterodimer,
thereby suppressing trans- and coactivation by nuclear
FoxO1, respectively.
CAAT enhancer-binding protein b (C/EBPb) (reviewed
in [42]) has been previously reported to coactivate STAT3
(43,44) as well as to interact with FoxO1 (45), implying
that C/EBPb family members (e.g., liver activating protein
[LAP], liver inhibiting protein [LIP], C/EBP homologous
protein [CHOP]) could mediate Maa suppression of FRE
transactivation or STAT3 coactivation by FoxO1. Indeed,
LAP and CHOP expression were induced by Maa (Fig. 6A
and B), and both coimmunoprecipitated with nuclear
FoxO1 (Fig. 6C). Moreover, FoxO1-induced expression of
the FRE reporter plasmid was robustly inhibited by
overexpressing LAP, LIP, or CHOP in decreasing order
(Fig. 6D), indicating that Maa-induced C/EBPb isoforms
could suppress transactivation by nuclear FoxO1. Similarly,
coactivation of STAT3-C by FoxO1 was completely abro-
gated by overexpressing LAP (Fig. 6E), indicating that Maa-
induced C/EBPb isoforms may suppress coactivation of
STAT3 by nuclear FoxO1. It is noteworthy that sup-
pression of FoxO1 coactivation of STAT3 by LAP domi-
nates over LAP coactivation of STAT3 (43,44), resulting in
overall suppression of STAT3 activity by LAP under con-
ditions of nuclear FoxO1 activity (Fig. 6E).
The causal role played by C/EBPb family members in
transducing suppression of nuclear FoxO1 by Maa was
veriﬁed in CHOP
2/2 MEF (28), where Maa failed to induce
the expression of LAP (Fig. 6F). In contrast with CHOP
+/+
MEF, Maa failed to suppress FoxO1 in CHOP
2/2 MEF (Fig.
6F), indicating that inhibition of nuclear FoxO1 activity by
Maa is transduced by Maa-induced C/EBPb isoforms.
Previous reports concerned with the mode of suppres-
sion of FoxO1 by insulin have focused on insulin activity
in exporting nuclear FoxO1 by its phosphorylation by
FIG. 3. Suppression of FoxO1 transcriptional trans- and coactivation by Maa and metformin. A: Cos7 cells were transfected with FoxO1 reporter
plasmid (FRE3-TK-LUC) and cotransfected with empty (–), FoxO1(TSS), or FoxO1(AAA) expression plasmids as indicated, in the presence of
vehicle (black bars), 150 mmol/L Maa (empty bars), or 2.0 mmol/L metformin (cross-hatched bars) as described in RESEARCH DESIGN AND METHODS.
Luciferase activity of cells transfected with an empty plasmid normalized to b-galactosidase was deﬁned as 1.0. Mean 6 SE for three in-
dependent experiments. *Signiﬁcant as compared with empty-transfected cells (P < 0.05); #signiﬁcant as compared with respective vehicle-
treated cells (P < 0.05). B: Cos7 cells were transfected with STAT3 reporter plasmid (M67-TATA-TK-LUC) and cotransfected with empty (–),
STAT3-C, FoxO1(TSS), or FoxO1(AAA) expression plasmids as indicated, in the presence of vehicle (black bars), 150 mmol/L Maa (empty
bars), or 2.0 mmol/L metformin (dotted bars) as described in RESEARCH DESIGN AND METHODS. Luciferase activity of empty-transfected cells nor-
malized to b-galactosidase was deﬁned as 1.0. Mean 6 SE for three independent experiments. *Signiﬁcant as compared with empty-transfected
cells (P < 0.05); #signiﬁcant as compared with respective vehicle-treated cells (P < 0.05).
SUPPRESSION OF FoxO1 BY FATTY ACYL ANALOGS
1876 DIABETES, VOL. 60, JULY 2011 diabetes.diabetesjournals.orgactivated Akt (1). Suppression of nuclear FoxO1 activity
by Maa-induced C/EBPb isoforms has prompted us to
further pursue similar suppression of nuclear FoxO1 by
insulin. Indeed, insulin treatment increased protein levels
of LAP and CHOP (Fig. 7A), in line with suppressed
transactivation of the FRE/IGFBP-1 reporter plasmid by
nuclear FoxO1(AAA) (Fig. 7B) (46). These results indicate
that suppression of wild-type FoxO1(TSS) by insulin may
FIG. 4. Nuclear exclusion and decrease in cellular FoxO1 induced by Maa. A and B: HepG2 cells grown on cover slips were transfected with
expression plasmids for GFP-FoxO1(TSS) in the absence or presence of DN-AMPK as indicated. After transfection (24 h), the culture medium was
changed to serum-free DMEM supplemented with vehicle (black bars), 0.1 mmol/L insulin (hatched bars), 200 mmol/L Maa (empty bars), or 2.0
mmol/L metformin (cross-hatched bars) as indicated, and further incubated for 24 h before ﬁxation and DAPI staining. A: Representative im-
munoﬂuorescence slides of GFP-FoxO1 (green) and DAPI-stained nuclei (blue; bar 20 mm). B: Nuclear-to-cytosolic ratio analyzed using ﬂuo-
rescence microscopy (Axioskop). Mean 6 SE of three independent experiments. *Signiﬁcant as compared with vehicle-treated cells (P < 0.05). C:
HepG2 cells were incubated for 3 h in serum-free DMEM supplemented with 0.1 mmol/L insulin, 200 mmol/L Maa, or 2.0 mmol/L metformin as
indicated. Cell extracts were subjected to SDS-PAGE followed by Western blotting as described in RESEARCH DESIGN AND METHODS. Blots were probed
with anti- P-FoxO1(T24), FoxO1, P-AMPK(T172), AMPK, P-ACC(S79), ACC, or tubulin antibodies. Representative blots of three independent
experiments. D: SD rats were dosed daily by gavage for 2 weeks with vehicle (black bars) or with 80 mg Maa/kg BW in 1% CMC (empty bars). hCRP
transgenic mice were dosed with 0.06% (W/W) Maa mixed in the diet for a period of 3 weeks (empty bars) or kept untreated (black bars). Liver
extracts were subjected to SDS-PAGE followed by Western blotting as described in RESEARCH DESIGN AND METHODS. Blots were probed with anti-FoxO1
antibodies normalized to tubulin or P-AMPK(T172) antibodies normalized to AMPK. Hepatic FoxO1 content normalized to tubulin and P-AMPK
(T172)-to-AMPK ratio of nontreated animals is deﬁned as 1.0. Mean 6 SE (n = 4 to 5). *Signiﬁcant as compared with nontreated animals (P <
0.05). Inset: Representative blots. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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phosphorylation of its Akt consensus sites as well as in-
hibition of its nuclear transcriptional activity by insulin-
induced C/EBPb isoforms.
DISCUSSION
The ﬁndings reported here may indicate that suppres-
sion of FoxO1 transcriptional activity by Maa may be
ascribed to its nuclear exclusion by Maa-activated AMPK,
complemented by suppression of its nuclear transcrip-
tional activity by Maa-induced C/EBPb isoforms (Fig. 8).
Suppression of FoxO1 activity by Maa may indicate that
the insulin-sensitizing anti-inﬂammatory efﬁcacy of MEDICA
analogs previously reported in animal models of diabesity
(17–22), and further veriﬁed here in GP and in hCRP trans-
genic mice, may partly be accounted for by suppression of
FRE-responsive promoters (e.g., G6Pase, PEPCK, MTP,
apolipoprotein CIII, CD36, PDK4) by Maa as well as by
suppression of FoxO1 coactivation of STAT3-responsive
acute-phase genes (e.g., CRP, SAA, SAP). Suppression of
FoxO1 activity by Maa appears to mimic that of insulin.
Indeed, both induce the nuclear exclusion of FoxO1, and
further suppress nuclear FoxO1 activity by the induction
of C/EBPb isoforms (Fig. 8). Suppression of nuclear
FoxO1 activity by insulin, independently of its nuclear
exclusion extends the scope of insulin action beyond its
previously reported activity in exporting nuclear FoxO1
(1). In contrast with insulin and Maa, suppression of
FoxO1 activity by metformin appears to be essentially
accounted for by promoting nuclear exclusion of FoxO1
by metformin-activated AMPK (Fig. 8). It is worth noting
that metformin may also regulate gluconeogenesis by
FoxO1-independent mechanisms, including the suppression
of CREB/CBP/TORC2 activity (47), or by an AMPK/LKB1-
independent decrease in intracellular ATP (48), implying
that FoxO1, CREB/CBP/TORC2, and ATP levels may com-
plement each other in controlling hepatic glucose pro-
duction by metformin.
The proposed mode of action of MEDICA in suppressing
FoxO1 activity is in line with the following ﬁndings
reported herewith. First, treatment with Maa resulted in
decrease in the nuclear/cytosolic ratio of FoxO1, being
abrogated by DN-AMPK. Decreased levels of FoxO1 in-
duced by Maa-activated AMPK conform to previously
reported degradation of FoxO1 by AICAR-activated AMPK
in liver cells (40) or by shear stress-activated AMPK in
HUVEC (39). The mode of action of AMPK in exporting
FIG. 5. FoxO1 domains involved in suppression of FoxO1 by Maa. A: Cos7 cells were transfected as described in RESEARCH DESIGN AND METHODS with
(UAS)5-GAL4 reporter plasmid and with GAL4, GAL4-FoxO1(SS) (Daa211–655, S256, S319), or GAL4-FoxO1(AA) (Daa211–655, S256A, S319A)
expression plasmids as indicated, in the presence of vehicle (black bars) or 120 mmol/L Maa (empty bars). Luciferase activity of GAL4-transfected
cells normalized to b-galactosidase was deﬁned as 1.0. Mean 6 SE for three independent experiments. *Signiﬁcant as compared with GAL4-
transfected cells (P < 0.05). Nonsigniﬁcant as compared with respective vehicle-treated cells. B: Cos7 cells were transfected with STAT3(M67-
TATA-TK-Luciferase) reporter plasmid and with empty (–), STAT3-C, FoxO1(AAA), or GAL4-FoxO1(AA) (Daa211–655, S256A, S319A) as
indicated. Luciferase activity of empty-transfected cells normalized to b-galactosidase was deﬁned as 1.0. Mean 6 SE of three independent
experiments. *Signiﬁcant as compared with STAT3-C–transfected cells (P < 0.05). C: Cos7 cells lacking (lane 6) or overexpressing FoxO1
(AAA) (lanes 1–5) were cultured in the presence of vehicle (lanes 1–2) or 150 mMM aa (lanes 3–5) and in the presence of added anti-FoxO1
antibody (lane 5) as indicated. Labeled double-stranded oligonucleotide containing the FoxO1 binding site of the IGFBP-1 promoter (sense: 59-
cactaGCAAAACAAACTTATTTTGAACAC-39,a n t i s e n s e :5 9- GTGTGCAAAATAAGTTTGTTTTGctagtg-39) was prepared by the Klenow fragment of
DNA polymerase I and [
32P]dCTP. Nuclear extracts prepared from COS7 cells overexpressing FoxO1(AAA) were incubated with the labeled oligo-
nucleotide and subjected to 5% PAGE (29). FoxO1-DNA complex is indicated by an arrow. D: Cos7 cells transfected with empty (–)( lanes 3, 6)o r
with FoxO1(AAA), and STAT3-C expression plasmids (lanes 1, 4) were cultured in the presence of added 150 mmol/L Maa (lanes 2, 5)a si n d i c a t e d .
Nuclear extracts were immunoprecipitated as described in RESEARCH DESIGN AND METHODS with anti-STAT3 or -FoxO1 antibodies as indicated. Immu-
noprecipitates (lanes 1–3) and nuclear lysates (input) (lanes 4–6) were subjected to SDS-PAGE followed by Western blotting with anti-STAT3
or -FoxO1 antibodies as indicated. Representative blots of three independent experiments.
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and remains to be investigated. AMPK suppression of
FoxO1 activity, independently of Akt, has previously been
reported in shear-stressed HUVEC (39). Second, treatment
with Maa, but not with metformin, resulted in suppres-
sion of FoxO1(AAA) transcriptional activity, implying sup-
pression of nuclear FoxO1 activity. Finally, transactivation
by FoxO1 and coactivation of STAT3 by FoxO1 were in-
hibited by Maa-induced C/EBPb isoforms, whereas failure
to induce C/EBPb isoforms in CHOP
2/2 cells abrogated the
suppression of FoxO1 by Maa. The mode of induction of
C/EBPb isoforms by Maa still remains to be determined in
terms of expression and degradation of C/EBPb family
members.
It is important to note that the effects of MEDICA
compounds and AMPK on the function of FoxO proteins
may be isoform speciﬁc. Whereas FoxO1 is highly expressed
in insulin target tissues involved in regulating the diabetic
FIG. 6. Suppression of FoxO1 by Maa-induced C/EBPb isoforms. A: Cos7 cells were cultured for 16 h in the absence or presence of 150 mmol/L
Maa as described in RESEARCH DESIGN AND METHODS. Cellular extracts were subjected to SDS-PAGE followed by Western blotting as described in
RESEARCH DESIGN AND METHODS, using anti-LAP, -LIP, and -CHOP antibodies as indicated. Representative blots for LAP (35/32 kDa), LIP (20 kDa),
and CHOP (27 kDa). B: Cos7 cells were cultured in the absence (black bars) or presence (empty bars) of 150 mmol/L Maa as described in
RESEARCH DESIGN AND METHODS. Nuclear extracts were subjected to SDS-PAGE followed by Western blotting as described in RESEARCH DESIGN AND
METHODS, using anti-LAP, -LIP, and -CHOP antibodies as indicated. Loading was controlled by protein/lane. Nuclear LAP, LIP, and CHOP of
nontreated cells were deﬁned as 1.0. Mean 6 SE for three to four independent experiments for each of the C/EBP isoforms. *Signiﬁcant as
compared with nontreated cells (P < 0.05). Inset: Representative blots. C: Cos7 cells were transfected with empty (–) or FoxO1(AAA) ex-
pression plasmids as indicated. Nuclear extracts were immunoprecipitated as described in RESEARCH DESIGN AND METHODS with anti-LAP or -CHOP
antibodies as indicated. Immunoprecipitates and cellular lysates (input) were subjected to SDS-PAGE followed by Western blotting with anti-
FoxO1, -LAP, or -CHOP antibodies as indicated. Representative blots are shown. D: Cos7 cells were transfected with FoxO1 reporter plasmid
(FRE3-TK-Luciferase) and with expression plasmid for FoxO1(AAA) and were cotransfected with empty (–), LAP, LIP, or CHOP expression
plasmids as indicated. Luciferase activity of empty-transfected cells normalized to b-galactosidase was deﬁned as 1.0. Mean 6 SE for three
independent experiments for each C/EBP isoform. *Signiﬁcant as compared with empty-transfected cells (P < 0.05). Inset: Representative blots
of respective C/EBPb isoforms (upper lane) and tubulin (lower lane), indicating that C/EBPb isoforms were overexpressed to a similar extent.
E: Cos7 cells were transfected with STAT3 reporter plasmid (M67-TATA-TK-Luciferase) and cotransfected with empty (–), STAT3-C, FoxO1
(AAA), or LAP expression plasmids as indicated. Luciferase activity of empty-transfected cells normalized to b-galactosidase was deﬁned as 1.0.
Mean 6 SE for three independent experiments. *Signiﬁcant as compared with STAT3-C–transfected cells (P < 0.05). F: CHOP
+/+ and CHOP
2/2
MEF were transfected with FoxO1 reporter plasmid (FRE3-TK-Luciferase) and cotransfected with FoxO1(AAA) expression plasmid as de-
scribed in RESEARCH DESIGN AND METHODS, in the absence (black bars) or presence (empty bars) of 200 mmol/L Maa. Luciferase activity of vehicle-
treated CHOP
2/2 MEF was 3.2-fold higher as compared with CHOP
+/+ cells. Luciferase activity of respective vehicle-treated cells normalized to
b-galactosidase was deﬁned as 1.0. Mean 6 SE for three independent experiments. *Signiﬁcant as compared with vehicle-treated cells (P <
0.05). Inset:M aa- i n d u c e de x p r e s s i o no fL A Pa n dC H O Pi nC H O P
+/+ or CHOP
2/2 MEF. Representative blots are shown.
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the regulation of basic cellular functions, including re-
sistance to oxidative stress (e.g., SOD), cell cycle (e.g., p21,
p27), and apoptosis (e.g., BH3-only proteins, TNF-related
apoptosis-inducing ligand) (49). Moreover, whereas AMPK
suppresses FoxO1 activity and the diabetic phenotype
(39,40), AMPK directly phosphorylates COOH-terminal
amino acids of FoxO3a, resulting in activating the ex-
pression of FoxO3a-dependent genes coding for tumor
suppressors, cell cycle arrest, and survival (49). In con-
trast with AMPK-induced export of nuclear FoxO1, cel-
lular distribution of FoxO3a also was reported to remain
unaffected by AMPK (49). These differences between the
two FoxO factors in their response to AMPK may reﬂect
their distinct roles in yielding an overall positive response to
AMPK and AMPK activators in the FoxO1/metabolic versus
FoxO3a/survival contexts.
The insulin-mimetic effects of MEDICA analogs in sup-
pressing FoxO1 activity, combined with the previously
reported efﬁcacy of MEDICA analogs in treating insulin
resistance, hyperglycemia, diabetic dyslipidemia, and the
macrovascular disease of diabesity animal models (17–22),
suggest the intriguing possibility that endogenous free
LCFA might simulate the antidiabetic insulin-like effects of
MEDICA analogs, if allowed to reach high enough in-
tracellular concentrations while avoiding their esteriﬁca-
tion into downstream lipotoxic products by abrogating the
induction of glycerol-3-phosphate acyltransferases (GPAT)
by insulin (reviewed in [50]) and by limiting the availability
of glycerol-3-phpsphate. Hence, FoxO1 suppression by
MEDICA analogs may offer a molecular rationale for the
surprising efﬁcacy of carbohydrate-restricted diets in al-
leviating diabetes (13–15) and may point to the prospects
of synthetic substituted LCFA in treating diabetes.
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